Silgan vs Sonoco Products
SLGN and SON side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SLGN and SON compare
Silgan and Sonoco Products are about the same size, with market caps of $4.4B and $4.9B.
Silgan grew revenue faster over the last twelve months (4.5% versus 3.6% for Sonoco Products).
Silgan keeps more of each dollar of sales as profit, with a net margin of 3.9% compared with −3.1% at Sonoco Products.
Both pay dividends: Silgan yields 2.0% and Sonoco Products 3.2%.
Silgan scores higher on the StockData Score (12 against 7 for Sonoco Products), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SLGN | SON |
|---|---|---|
| Size and price | ||
| Market cap | $4.4B | $4.9B |
| Share price | $41.50 | $49.60 |
| Change, 1 year | 8.9% | 22.3% |
| Change, 5 years | −1.7% | −18.8% |
| Beta (5Y) | 0.66 | 0.72 |
| Employees | 13K | 23K |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 5 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 16.7× | – |
| P/S | 0.7× (better) | 0.7× |
| P/B | 1.8× | 1.8× (better) |
| EV/EBITDA | 9.5× (better) | 12.4× |
| P/FCF | 12.7× (better) | 14.0× |
| FCF yield | 7.9% (better) | 7.2% |
| Fair value | $52.48 | $42.24 |
| Margin of safety | 20.9% (better) | −17.4% |
| Growth | ||
| Revenue growth (TTM) | 4.5% (better) | 3.6% |
| Revenue growth, 5Y average | 5.7% | 7.0% (better) |
| Net income growth (TTM) | −16.9% (better) | −136% |
| EPS growth (TTM) | −15.6% (better) | −137% |
| EPS growth, 5Y average | −0.51% | 37.5% (better) |
| Profitability | ||
| Gross margin | 17.0% | 20.2% (better) |
| Operating margin | – | 2.7% |
| Net margin | 3.9% (better) | −3.1% |
| FCF margin | 5.2% (better) | 4.8% |
| Return on equity | 11.0% (better) | −7.4% |
| Return on invested capital | – | 2.1% |
| Financial health | ||
| Debt / equity | 1.84 | 1.53 (better) |
| Net debt / EBITDA | 4.68 (better) | 5.63 |
| Interest coverage | – | 1.1× |
| Current ratio | 1.35 (better) | 1.18 |
| Altman Z-score | 1.76 (better) | 1.61 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 2.0% | 3.2% (better) |
| Payout ratio | 33.7% | – |
| Years of dividend growth | 16 | 16 |
| Dividend growth, 5Y average | 10.8% (better) | 4.2% |
| Buyback yield | 0.38% (better) | 0.15% |
| Shareholder yield | 2.4% | 3.4% (better) |
| Ownership | ||
| Held by institutions | 92.5% | 98.6% |
| Held by insiders | 1.8% | 1.3% |
| Insider net buying, 12 months | $0 | $884K (better) |
| Short interest, % of float | 9.1% | 11.9% |
Go deeper
- SLGN stock overview
- SLGN income statement
- SLGN valuation and score
- SON stock overview
- SON income statement
- SON valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.